Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Pumitamig

Intravenous infusion

DRUG

Docetaxel

Intravenous infusion

Trial Locations (12)

5000

RECRUITING

Cancer Research SA (CRSA), Adelaide

10016

RECRUITING

NYU Langone - NYU Grossman School of Medicine, New York

21565

RECRUITING

Gachon University Gil Medical Center, Incheon

28644

RECRUITING

Chungbuk National University Hospital, Cheongju-si

33612

RECRUITING

Moffitt Cancer Center, Tampa

42701

RECRUITING

Baptist Health Hardin, Elizabethtown

52727

RECRUITING

Gyeongsang National University Hospital (GNUH), Jinju

77090

ACTIVE_NOT_RECRUITING

Texas Oncology, P.A., Houston

06351

RECRUITING

Samsung Medical Center, Seoul

CF14 2TL

RECRUITING

Velindre NHS Trust, Velindre Cancer Centre, Cardiff

LS9 7TF

RECRUITING

St James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds

W1G 6AD

RECRUITING

Sarah Cannon Research Institute, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioNTech SE

INDUSTRY